80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]陳培杰,白培明,羅廣承,等.原發(fā)與復(fù)發(fā)轉(zhuǎn)移性嗜鉻細胞瘤/副神經(jīng)節(jié)瘤的臨床特征對比分析[J].福建醫(yī)藥雜志,2022,44(02):4-6.
　CHEN Peijie,BAI Peiming,LUO Guangcheng,et al.Comparison and analysis of clinic features of primary and recurrent/metastatic phaeochromocytoma/paraganglioma[J].FUJIAN MEDICAL JOURNAL,2022,44(02):4-6.
點擊復(fù)制

原發(fā)與復(fù)發(fā)轉(zhuǎn)移性嗜鉻細胞瘤/副神經(jīng)節(jié)瘤的臨床特征對比分析()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
44
期數(shù):
2022年02期
頁碼:
4-6
欄目:
臨床研究
出版日期:
2022-04-15

文章信息/Info

Title:
Comparison and analysis of clinic features of primary and recurrent/metastatic phaeochromocytoma/paraganglioma
文章編號:
1002-2600(2022)02-0004-03
作者:
陳培杰; 白培明1; 羅廣承; 酈守國2; 陳雍君3
廈門大學(xué)附屬中山醫(yī)院泌尿外科(廈門 361004)
Author(s):
CHEN Peijie;  BAI Peiming;  LUO Guangcheng;  LI Shouguo;  CHEN Yongjun
Department of Urology, the Affiliated Zhongshan Hospital of Xiamen University, Xiamen, Fujian 361004, China
關(guān)鍵詞:
嗜鉻細胞瘤;  副神經(jīng)節(jié)瘤;  臨床特征;  預(yù)后
Keywords:
phaeochromocytoma;  paraganglioma;  clinic features;  prognosis
分類號:
R736.6
文獻標志碼:
B
摘要:
目的 分析原發(fā)與復(fù)發(fā)轉(zhuǎn)移性嗜鉻細胞瘤/副神經(jīng)節(jié)瘤(PPGL)患者的臨床特征差異,以改善復(fù)發(fā)轉(zhuǎn)移性患者的預(yù)后。方法 收集2011年6月至2021年6月我院各科室收治的107例PPGL患者資料并隨診; 對比原發(fā)與復(fù)發(fā)移性PPGL患者,以及對比復(fù)發(fā)轉(zhuǎn)移性嗜鉻細胞瘤與副神經(jīng)節(jié)瘤患者的有關(guān)臨床指標,并行統(tǒng)計分析。結(jié)果 大于5 cm的腫瘤、腫瘤內(nèi)壞死/液化、CgA強陽性(++)及Ki-67指數(shù)>5%的復(fù)發(fā)/轉(zhuǎn)移性PPGL患者比例,顯著高于原發(fā)性PPGL的比例,差異有統(tǒng)計學(xué)意義(P<0.05)。與復(fù)發(fā)/轉(zhuǎn)移性嗜鉻細胞瘤相比,復(fù)發(fā)/轉(zhuǎn)移性副神經(jīng)節(jié)瘤更大、更易液化壞死,CgA強陽性和Ki-67指數(shù)>5%的比例更高(P<0.05)。結(jié)論 大于5 cm的腫瘤、腫瘤內(nèi)液化壞死、Ki67指數(shù)高以及CgA強陽性的PPGL患者,發(fā)生復(fù)發(fā)/轉(zhuǎn)移的可能性大; 相對于嗜鉻細胞瘤,副神經(jīng)節(jié)瘤的患者更易出現(xiàn)復(fù)發(fā)和轉(zhuǎn)移,其預(yù)后也更差。
Abstract:
Objective In order to improve the prognosis of recurrent and metastatic phaeochromocytoma/paraganglioma(PPGL), analysis of clinic features of primary and recurrent/metastatic PPGL.Methods A total of 107 cases of PPGL in our hospital were recruited from Jun 2010 to Jun 2021.Clinic features of primary PPGL and recurrent/metastatic PPGL, and those of recurrent/metastatic phaeochromocytoma and recurrent/metastatic paraganglioma were compared and analyzed statistically.Results The patient proportion of tumor >5 cm in diameter、tumor necrosis and liguefaction、strong positive CgA and >5% Ki-67 index in recurrent/metastatic PPGL were statistically higher than those in primary PPGL(P<0.05).Compared with recurrent/metastatic phaeochromocytoma, recurrent/metastatic paraganglioma were lager,leading to necrosis and liguefaction more easily,and the patient proportion of strong positive CgA and >5% Ki-67 index were statistically higher(P<0.05).Conclusion Patient of the PPGL with tumor >5 cm in diameter,tumor necrosis and liguefaction,strong positive CgA and >5% Ki-67 index,become more recurrent and metastatic likely.Compared with phaeochromocytoma,paraganglioma is more recurrent and metastatic easily with poorer prognosis.

參考文獻/References:

[1] 嗜鉻細胞瘤和副神經(jīng)節(jié)瘤診斷治療專家共識(2020 版)[J].中華內(nèi)分泌代謝雜志,2020,36(9):737-750.
[2] Hamidi O,Young W F Jr,Gruber L, et al.Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis[J].Clin Endocrinol(Oxf),2017,87: 440-450.
[3] Lam A K.Update on adrenal tumors in 2017 World Health Organization(WHO)of endocrine tumors[J].Endoer Pathol,2017,28(3):213-227.
[4] 鄧建華,李漢忠.轉(zhuǎn)移性嗜鉻細胞瘤/副神經(jīng)節(jié)瘤的臨床診斷和預(yù)后[J].協(xié)和醫(yī)學(xué)雜志,2019,10(6):654-659.
[5] Kimura N,Takayanagi R,Takizawa N,et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma[J]. Endocr Relat Cancer,2014,21: 405-414.
[6] 林潔,郭慈仁,陳雪燕, 等.P16蛋白和Ki-67抗原在宮頸上皮內(nèi)瘤變分級診斷中的價值[J].福建醫(yī)藥雜志,2021,43(6):16-17.
[7] Azizan N, Hayati F, Tizen N M S,et al.Role of coexpression of estrogen receptor beta and Ki-67 in prostate adenocarcinoma[J].Investig Clin Urol, 2018,59(4):232-237.
[8] Domínguez N,Estévez-Herrera J,Pardo M R,et al.The functional role of chromogranin in exocytosis[J].J Mol Neurosci,2012,48(2):317-322.

備注/Memo

備注/Memo:
1 通信作者,Email:[email protected]; 2 腫瘤放療科; 3 脊柱外科
更新日期/Last Update: 2022-04-15